Rachit Khandelwal, Pediatrics BMT fellow at Medanta The Medicity, shared an article by Hamenth Kumar Palani, et al. on X:
“India’s First POC CAR-T Trial: VELCART.
Point-of-care anti-CD19 CAR-T therapy shows 100% CR in B-ALL, low cost and no serious toxicity.
A breakthrough for LMICs—accessible, affordable, effective.
Published in Molecular Therapy Oncology.”
Safety, efficacy and total cost of point-of-care manufactured anti-CD19 CAR-T cell therapy in India: VELCART trial.
Authors: Hamenth Kumar Palani, et al.
